Fabíola Traina in research grants and scholarships supported by FAPESP.
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
We propose a program of basic and clinical research to isolate, culture, and characterize embryonic ,somatic, and neoplastic stem cells in order to understand their biology and apply this knowledge to therapy, comprising four research lines: (1) pluripotent stem cells (SC) (embryonic SC and induced pluripotent SC); (2) somatic SC (hematopoietic SC, mesenchymal SC, endothelial SC, and canc…
Myeloproliferative neoplasia originates from the hematopoietic stem cell, are characterized by JAK/STAT signaling activation, and decontrolled proliferation of one or more cells of the myeloid lineage. Patients may present changes in hematimetric counts, splenomegaly, and thromboembolic events, and evolve with increased fibrosis in the bone marrow and acute myeloid leukemia. The only pote…
Hematopoiesis is a process finely regulated by cytokines and growth factors. The regulation of these molecules depends, among other factors, on the action of cytoplasmic adapter proteins, such as insulin receptor substrates (IRS). IRS activation promotes the recruitment of effector proteins involved in the regulation of JAK/STAT, PI3K/AKT/mTOR and MAPK signaling. These signaling pathways …
The BCR-ABL1 negative chronic myeloproliferative neoplasms (MPN) are characterized by increased cellular proliferation with preserved terminal myeloid differentiation. In most cases, the activation of cell proliferation is caused by an increased tyrosine kinase activity of specific proteins. However, patients' molecular heterogeneity and the incomplete clinical responses observed in part …
(Only some records are available in English at this moment)
Acute myeloid leukemia (AML) comprehends a heterogeneous and complex group of hematological neoplasms characterized by the affection of hematopoietic stem and progenitor cells by (epi)genetic insults that trigger these cells clonal expansion, hypofunctional cells accumulation and bone marrow remodeling that leads to impairment of normal hematopoiesis.AML's biology has been extensively stu…
FLT3 gene mutations are present on near 30% of the acute myeloid leukemia (AML) patients with FLT3-ITD being the most frequent among other FLT3 mutations and related to a poor prognosis. The development of FLT3 inhibitors stated an improvement on AML treatment since they are able to reduce cell proliferation and ameliorate patients' survival. However, clinical limitations on using these d…
Chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (aCML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS) / myeloproliferative neoplasm (MPN) unclassified are rare myeloid neoplasms with overlapping laboratory and molecular characteristics, challenging the differential diagnosis and the development of therapies. Mutations in the CSF3R gene, w…
Acute myeloid leukemia (AML) is the ninth most prevalent cancer in Brazil and represents a heterogeneous group of diseases. Expansion (e20 %) of the bone marrow or peripheral blood myeloblastic progenitor is diagnostic criterion for AML. For diagnosis and risk stratification, peripheral blood and bone marrow smear analysis, immunophenotyping and karyotype are needed. Genetic alterations, …
Hematopoiesis regulation depends, among other factors, on the action of cytoplasmic adapter proteins, such as insulin receptor substrates (IRS). Previous study conducted by our research group indicated that IRS1 and IRS2 are differentially expressed in hematological malignancies, including myelodysplastic syndromes and acute leukemias. Our group also demonstrated that IRS2 is recruited du…
(Only some records are available in English at this moment)
Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm (MPN). The overlapping features of CNL with others rare myeloid malignancies, have been challenging the differential diagnosis and the development of therapies. Mutations in the CSF3R gene, which encodes the granulocyte colony stimulating factor receptor (G-CSFR), occur in CNL and result in the activation of JAK/STA…
The epigenetic modifier additional sex combs-like 1 (ASXL1) is frequently mutated and associated with a poor prognosis across myeloid neoplasms, including myeloproliferative neoplasms (MPN). Frameshift ASXL1 mutations located in the last exon produce a C-terminally truncated mutant protein that promotes myeloid transformation by altering histone modifications potentially in both a dominan…
Chronic myeloid leukemia (CML) is a hematological malignancy associated with the BCR-ABL1 fusion gene, which drives the proliferative disease phenotype by activating multiple signaling pathways. Most CML patients are successfully treated with tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1. However, acquired drug resistance limits TKI efficacy in a significant subset of patients, war…
| 1 / 1 | Ongoing research grants |
| 9 / 8 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 15 / 14 | Completed scholarships in Brazil |
| 3 / 3 | Completed scholarships abroad |
| 30 / 28 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID